Citigroup Inc Relmada Therapeutics, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 62,951 shares of RLMD stock, worth $23,921. This represents 0.0% of its overall portfolio holdings.

Number of Shares

62,951

Previous 62,951 -0.0%

Holding current value

$23,921

Previous $188,000 7.98%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$2.93 - $4.94 $178,325 - $300,658	-60,862 Reduced 49.16%	62,951 $188,000
Q1 2024 May 10, 2024	BUY	$3.1 - $6.8 $157,139 - $344,692	50,690 Added 69.32%	123,813 $575,000
Q4 2023 Feb 09, 2024	SELL	$2.45 - $4.22 $64,680 - $111,408	-26,400 Reduced 26.53%	73,123 $302,000
Q3 2023 Nov 09, 2023	SELL	$2.48 - $3.79 $49,091 - $75,023	-19,795 Reduced 16.59%	99,523 $298,000
Q2 2023 Aug 10, 2023	BUY	$2.22 - $3.54 $264,885 - $422,385	119,318 New	119,318 $293,000
Q4 2022 Feb 09, 2023	SELL	$2.17 - $35.84 $8,673 - $143,252	-3,997 Reduced 95.58%	185 $0
Q3 2022 Nov 10, 2022	SELL	$18.3 - $37.02 $1.07 Million - $2.17 Million	-58,519 Reduced 93.33%	4,182 $155,000
Q2 2022 Aug 10, 2022	BUY	$16.5 - $30.34 $458,634 - $843,330	27,796 Added 79.63%	62,701 $1.19 Million
Q1 2022 May 12, 2022	BUY	$16.72 - $26.99 $499,777 - $806,758	29,891 Added 596.15%	34,905 $942,000
Q4 2021 Feb 10, 2022	SELL	$16.93 - $26.82 $48,876 - $77,429	-2,887 Reduced 36.54%	5,014 $113,000
Q3 2021 Nov 10, 2021	BUY	$21.86 - $34.77 $172,715 - $274,717	7,901 New	7,901 $207,000

Others Institutions Holding RLMD

# of Institutions

Shares Held

12.3M

Call Options Held

229K

Put Options Held

138K

View Full List

About RELMADA THERAPEUTICS, INC.

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

More about RLMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account